… In conclusion, this SLR informed the EULAR initiative to formulate PtC on COVID-19
pathophysiology and immunomodulatory therapies. However, the results of the present SLR also …

… SARS-CoV-2 monoclonal antibodies showed efficacy in subjects not mounting normal
anti-SARS-CoV… This SLR informed the 2021 update of the EULAR points to consider on the use of …

… (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of
recommendations as a ‘living document’ and a starting point, which will be updated as soon as …

… The aim of this project was to update the EULAR points to Consider (PtC) on the use of …
for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. …

… EULAR’s first set of provisional recommendations addressing several clinical aspects of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV… to inform EULAR points to consider…

… Five longitudinal studies assessing anti-SARS CoV-2 IgM and IgG using commercially
available assays were included (table 6).50–54 Three studies used ELISA,50 51 53 while two …

… In conclusion, these EULAR PtCs provide relevant guidance on the pathophysiology of
SARS-COV-2 infection, especially immunomodulatory therapy utilisation from the rheumatology …

… EULAR … EULAR did not advise temporarily stopping or adjusting the timing of any of these
medications (with the exception of rituximab) relative to when the vaccine against SARS-CoV-…

… In this perspective, the constitution of dedicated task forces, such as those promoted by
EULAR1 as well as by other national and international societies,9 10 is fundamental to assist …

… This SLR was used to inform the EULAR task force for the July 2021 update of the
recommendations for the management of RMDs in the context of SARS-CoV-2. The task force …